Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
143
resultados
Última actualización
27/03/2025 [07:42:00]
Resumen de: WO2023225244A1
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is of therapeutic benefit, specifically in treating Huntington disease ("HD"). This disclosure also features a composition containing the same as well as methods of using and making the same.
Resumen de: CN119212693A
Provided herein are methods and compositions for the treatment of neurodegenerative diseases (e.g., ALS). The methods may comprise administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyric acid compound.
Resumen de: WO2023222924A1
The present invention concerns Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or Alzheimer's disease-related origin. The present invention also provides compositions, in particular, an oral composition, comprising the Lachnospiraceae spp and Ruminococcus lactaris strains and uses thereof.
Resumen de: EP4528274A2
The invention relates to the use of biomarkers of TrkB-FL, TrkB-ICD, TrkB-T', the TrkB-T':TrkB-FL ratio, or the TrkB-ICD:TrkB-FL ratio in the in vitro diagnosis of Alzheimer Disease (AD) or for determining the stage of AD, methods for their use, methods of diagnosis, methods of monitoring disease progression, in neuropathological diseases, in particular for Alzheimer's disease.
Resumen de: WO2025059486A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Resumen de: WO2025056518A1
The present invention relates to the field of medicinal chemistry and more specifically to 5,6- disubstituted 1H- and 2H- indazoles as pharmaceutically active compounds. The compounds of the present invention are dual inhibitors of butyrylcholinesterase and p38α mitogen-activated protein kinase, and thus are particularly useful for the treatment of various diseases which may be therapeutically modified by altering the activity of butyrylcholinesterase (BChE) and/or p38α MAP kinase such as dementias including Alzheimer's disease (AD) and other conditions involving chronic inflammation.
Resumen de: US2025090505A1
Provided herein are methods for preventing biomineralization in brain tissue or neuronal tissue in vivo or in vitro by inhibiting the deposition of hydroxyapatite therein. Also provided are methods for delaying the progression or onset of Alzheimer's disease in a subject and for preventing the development of Alzheimer's disease in a post-traumatic brain injury subject. Contacting the brain tissue or neuronal tissue with or administering to a subject the drugs Levamisole and/or Foscarnet and/or a bisphosphonate inhibits or decreases levels of alkaline phosphatase and calcium and counteracts alpha-glycerophosphate therein to inhibit the activation of spontaneous biomineralization within a brain tissue to decrease or prevent ectopic biomineralization.
Resumen de: US2025090541A1
Disclosed are methods for treating or inhibiting development of a disorder selected from the group consisting of a frontotemporal dementia (FTD), Pick's disease, progressive supranuclear palsy, Huntington's disease, Parkinson's disease, corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Lewy body disease, and hippocampal sclerosis (HS), by administering a compound of formula I.
Resumen de: AU2025201237A1
METHODS FOR TREATING ALZHEIMER'S DISEASE A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
Resumen de: AU2023348297A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: AU2025201530A1
The present disclosure is in the field of modulation of genes involved in rare diseases including for diagnostics and therapeutics for rare diseases such as Angelman's Syndrome, 5 Facioscapulohumeral Muscular Dystrophy (FHMD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia (FTD) and Spinal Muscular Atrophy (SMA).
Resumen de: WO2025059104A1
Described are methods of treating a neurodegenerative disease, such as an age- related neurodegenerative disease in a patient in need thereof, comprising administering a composition comprising a therapeutically effective amount of at least one human milk oligosaccharide (HMO). Also described are methods of treating Parkinson's Disease (PD) in a patient in need thereof comprising administering to said patient an effective amount of an HMO.
Resumen de: WO2025058473A1
The present invention relates to: a pharmaceutical composition for selectively preventing or treating neurodegenerative diseases including Parkinson's disease, comprising as an active ingredient exosomes into which has been delivered a degenerative brain disease-therapeutic protein via a photocleavable protein; and a method for preparing same. Parkinson's disease therapeutic proteins, such as Parkin protein, effectively inhibit the death of damaged dopaminergic neurons, and have protective effects against neurotoxic substances, and thus have an effect of preventing damage to neurons.
Resumen de: US2025092064A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: US2025090571A1
Provided herein are methods and compositions to enhance or activate protective microglial activities (such as phagocytosis of neurotoxic material) by activating CARD9.
Resumen de: US2025090568A1
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
Resumen de: WO2025058089A1
The purpose of the present invention is to provide an agent for suppressing amyloid β aggregation/deposition and an agent for suppressing/improving cognitive decline of a subject both of which are expected to have the effect of treating and/or preventing Alzheimer's disease. Specifically, the present invention pertains to an agent for suppressing amyloid β aggregation/deposition or an agent for suppressing/improving cognitive decline of a subject, the agent comprising an extract of a plant belonging to Myrtaceae.
Resumen de: WO2025056018A1
Provided is the new compositions and methods useful for the treatment, prevention, and potential cure of a genetic disease, such as familial Alzheimer's Disease, by disrupting the genomic sequence harboring one or more SNPs that are of high prevalence in a population but no relevance to the particular disease except for their genomic locations being in the same gene exon as a disease-relevant allele and upstream from such disease-relevant allele present in the genome of a treatment recipient.
Resumen de: WO2023218187A1
Disclosed are heterobifunctional compounds that can induce the degradation of leucine-rich repeat kinase 2 (LRRK2) and PDE6D. These compounds can engage LRRK2 on one end and bind to an ubiquitin E3 ligase (e.g. cereblon, Von Hippel-Lindau, or Cellular Inhibitor of Apoptosis (cIAP)) on the other end and therefore bring LRRK2 in close proximity to the E3 ligase and induce the ubiquitination and degradation of the LRRK2 protein. Also disclosed are pharmaceutical composition comprising the heterobifunctional compounds and methods of using the compounds to treat LRRK2 and PDE6D- related diseases and disorders.
Resumen de: AU2023269025A1
Disclosed are therapeutic methods for reducing the rate of functionality loss in patients suffering from amyotrophic lateral sclerosis (ALS) during the accelerated stages of this disease.
Resumen de: AU2023267136A1
This application includes methods for reducing axonal tau protein. Those methods include inhibiting the binding between MAPT mRNA and hnRNP R.
Resumen de: WO2025053670A1
The present invention relates to a vanillic acid derivative compound, which can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a composition for treating Alzheimer's disease and a composition for treating neuroinflammation, the compositions comprising the compound.
Resumen de: WO2025053994A1
Described herein are compounds that increase levels of sCLU (clusterin secreted isoform) and associated methods of treating Alzheimer's disease, diabetes and cardiovascular disease.
Resumen de: WO2025051280A1
The present invention belongs to the field of traditional Chinese medicine, and specifically relates to the use of a traditional Chinese medicine composition in the preparation of a pharmaceutical for preventing or/and treating amyotrophic lateral sclerosis. Specifically, the traditional Chinese medicine composition is prepared from herba schizonepetae, radix saposhnikoviae divaricatae, rhizoma seu radix notopterygii, radix angelicae pubescentis, radix bupleuri, radix peucedani, rhizoma chuanxiong, fructus aurantii, poria cocos, radix platycodi, and radix glycyrrhizae. Pharmacodynamic test results show that the traditional Chinese medicine composition provided by the present invention can prolong survival, maintain weight increase, and increase the limb strength of amyotrophic lateral sclerosis mouse models, has the effects of delaying the progression of muscle atrophy and delaying motor neuron apoptosis, and has a precise therapeutic effect for treating amyotrophic lateral sclerosis.
Nº publicación: WO2025051214A1 13/03/2025
Solicitante:
INNOVSTONE THERAPEUTICS LTD [CN]
\u4E0A\u6D77\u7FCA\u77F3\u533B\u836F\u79D1\u6280\u6709\u9650\u516C\u53F8
Resumen de: WO2025051214A1
Provided are a compound having a new structure and serving as an LRRK2 inhibitor, and a stereoisomer, optical isomer, and pharmaceutically acceptable salt thereof. A new direction is provided for the development of LRRK2 inhibitor drugs. In vitro enzyme and cell activity inhibition studies show that these compounds all have a strong inhibitory effect, and can be used as promising compounds for treating and/or preventing LRRK2-mediated diseases (such as neurodegenerative diseases, especially Parkinson's disease).
BOPI
Sede Electrónica
